{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.427","value":"0.50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"description":"Serum golimumab trough concentration at Week 28 was reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 80 milligrams per meter square (mg/m\\^2) golimumab as an intravenous (IV) infusion at Weeks 0, 4, and then every 8 weeks (q8w) till Week 52. Participants also received commercial methotrexate (MTX) weekly through Week 28 at the same body surface area (BSA)-based dosage (10 to 30 mg/m\\^2 per week for participants with BSA less than \\[\\<\\] 1.67 meter square \\[m\\^2\\], or minimum of 15 mg/week for participants with BSA greater than or equal to \\[\\>=\\] 1.67 m\\^2) as at time of study entry. After Week 28, changes in MTX administration were permitted. Participants who completed Week 52 had the option to enter into the long-term extension (LTE) phase. Participants who opted not to enter the LTE completed an additional 8-week safety follow-up visit following the last administration of the study agent. Participants who entered LTE continued to receive 80 mg/m\\^2 IV golimumab q8w through Week 244. All participants who completed Week 244 were followed for safety through Week 252. Participants who met the inclusion criteria entered the extended treatment period (ETP) and continued to receive 80 mg/m\\^2 IV golimumab q8w from Week 252 to Week 420.","id":"OG000","title":"Golimumab"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic (PK) analysis set included all treated participants (who received at least 1 infusion) who have sufficient PK samples for analysis. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 28","title":"Serum Trough Concentration (C-trough) of Golimumab","type":"PRIMARY","unitOfMeasure":"micrograms per milliliter (mcg/mL)"}